Searched for
ALEMBIC PHARMACEUTICALS SHARE PRICE
Diksha Polymers IPO opens today. Check GMP, subscription, and other detailsThe allotment is expected to be finalised on June 22, while the shares are scheduled to list on the BSE SME platform on June 24.- Leapfrog Engineering Services IPO: Check GMP, price band, subscription and other detailsThe IPO comprises a fresh issue of 3.46 crore shares aggregating Rs 79.6 crore and an offer for sale of 38.76 lakh shares worth Rs 8.91 cro...
- API prices fall as West Asia tensions ease, boosting Indian pharma sectorPrices for active pharmaceutical ingredients have seen a decline of five to ten percent, thanks to the calming geopolitical climate in West...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27%The US-Iran peace deal is finally about to happen. There is a high probability that global markets will see a relief rally, a part of which...
- Two Trades for Today: A realty major for a 6.6% rise, a mid-cap fertiliser maker’s stock for a 7% gainOur technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Time for investors and traders to think alike? 7 Nifty Auto stocks with an upside potential of up to 19%There are sectors that have not quite followed the war script. Take the auto sector, for instance. A surge in oil prices is supposed to be ...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Leapfrog Engineering Services IPO to open on Wed at Rs 21-23 per shareLeapfrog Engineering Services Ltd has set its IPO price band at Rs 21-23 per share, opening for subscription on June 17, 2026. The Rs 88.51...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Two Trades for Today: 2 pharma companies – a large-cap for a 5% rise, and a mid-cap stock for a gain of 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- India raises price cap on cancer drugs to tackle shortageIndia's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...
- Government may lift price cap on cancer drugs making them costlier by up to 50%India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy age...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe latest escalation in the US-Iran war means that crude oil price is back as a risk for India. Although we are in a market already strugg...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
Load More
